The European Medicines Agency re-examined clinical data of a subset of patients with one or no copies of the APOE4 gene ...
European regulators initially said in July that the drug's benefits did not outweigh its risks. View on euronews ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback